Congestive heart failure (CHF) is a physiological condition that has an adverse impact on the pumping efficiency of the cardiac muscles. It characterizes the accumulation of fluid around the heart leading to inefficient pumping. The onset of CHF is marked by the failure of the ventricles to pump sufficient volume of blood to the body organs. This eventually leads to deposition of fluid in the lungs, abdomen, liver, and lower body. CHF is treated by a number of devices that maintain heart rhythm, such as pacemakers, cardiac resynchronization therapy (CRT), implantable cardioverter defibrillators (ICDs), and ventricular assist devices (VADs).
The world CHF treatment devices market was evaluated at $10,127.2 million in 2015, and is estimated to reach $14,823.3 million by 2022, with a CAGR of 5.5% over the forecast period. This is primarily attributed to the constantly changing lifestyle habits (such as unhealthy dietary habits, excessive alcohol consumption, smoking, obesity, and lack of physical activity) which make individuals more susceptible to arrhythmia and heart failure. In addition, a number of factors such as the large number of technological advancements in CHF treatment devices, increased adoption rate of these devices, and rising emphasis on early intervention and primary prevention of heart-related disorders are responsible for driving the market. Conversely, stringent government regulations for the approval of CHF treatment devices, high cost of, and high preference to drugs for CHF treatment are some of the factors restraining the market growth.
The report segments the world CHF treatment devices market based on product type, namely, pacemakers, cardiac resynchronization therapy (CRT) devices, implantable cardioverter defibrillators (ICDs), and ventricular assist devices (VADs). Pacemaker is further segmented into dual-chamber pacemakers and single-chamber pacemakers. CRT devices is segmented into two major types, namely, CRT-P and CRT-D. ICDs is further segmented into transvenous implantable cardioverter defibrillator (T-ICDs) and subcutaneous implantable cardioverter defibrillator (S-ICDs). VADs is also segmented into left ventricular assist device (LVAD), right ventricular assist device (RVAD), and biventricular assist device (BIVAD). ICDs was the highest revenue-generating segment in 2015, owing to the stressful hyperactive lifestyle, unhealthy food habits, and growing number of aging population. Based on geography, the market is divided into North America, Europe, Asia-Pacific, and LAMEA regions.
The key players in this market adopted product development and product launch as their key strategies to keep pace with the changing demands of consumers. Furthermore, companies launched cost-effective and technologically efficient products to strengthen their market position. The report provides a comprehensive analysis of the key players operating in the world CHF treatment devices market, such as Abiomed, Inc., Berlin Heart GmbH, Biotronik SE & Co. KG, Boston Scientific Corporation, HeartWare International, Inc., Jarvik Heart, Inc., LivaNova PLC, Medtronic plc, ReliantHeart Inc., and St. Jude Medical, Inc.
CONGESTIVE HEART FAILURE (CHF) TREATMENT DEVICES MARKET KEY SEGMENTS:
Congestive Heart Failure (CHF) Treatment Devices Market, By Product
Pacemakers, By Type
Cardiac Resynchronization Therapy (CRT), By Type
Implantable Cardioverter Defibrillators (ICDs), By Type
Ventricular Assist Devices (VADs), By Type
SIMILAR MARKET STUDIES
Glucose Meter is a medical device for determining the approximate concentration of glucose in the blood. It can also be a strip of glucose paper dipped into a substance and measured to the glucose chart. It is a key element of home blood glucose monitoring (HBGM) by people with diabetes ...
September 2017 | $4880 | View Details >>
This report studies the Pet Insurance market, Pet insurance is a type of specialty property and casualty insurance policy that pet owners purchase to cover the unintended costs that arise in providing care for a pet, including veterinary services such as surgical procedures, injuries from accidents, and prescribed pet medicines. ...
September 2017 | $4880 | View Details >>
Geographically, this report is segmented into several key Regions, with production, consumption, revenue, market share and growth rate of Biofeedback Instrument in these regions, from 2012 to 2022 (forecast), covering North America Europe China Asia (Ex. China) RoW The major players in global Biofeedback Instrument market include Thought Technology Ltd Laborie Qxsubspace Vishee Quantum World Vision BrainMaster Technologies, Inc. Mind Media NeuroCare Allengers Medical Systems ELMIKO NCC ...
September 2017 | $2900 | View Details >>
This report studies the Irreversible Electroporation Ablators market status and outlook of global and major regions, from angles of players, regions, product types and end industries; this report analyzes the top players in global and major regions, and splits the Irreversible Electroporation Ablators market by product type and applications/end industries. The ...
September 2017 | $4000 | View Details >>
UPCOMING MARKET RESEARCH REPORTS
2017 © Copyright Big Market Research